Full thickness.

KEYNOTE-629 won FDA approval for pembrolizumab to expand its territory to cutaneous squamous cell carcinoma not amenable to curative surgery. It’s full manuscript is now out detailing a median progression-free survival of 7 months. | Grob, J Clin Oncol 2020